Wall Street is positive on Sellas Life Sciences Group Inc (SLS). On average, analysts give the stock a Strong Buy rating. The average price target is $6.25, which means analysts expect the stock to climb by 243.41% over the next twelve months.
That average ranking earns the stock an Analyst Rating of 80, which is better than 80% of stocks based on data compiled by InvestorsObserver.
Why are Analyst Ratings Important?
Though analyst projections should not be your only resource when determining your position on a stock, it can be a very useful tool. Analysts follow sectors/industries in-depth and tend to know how local and global conditions tend to affect demand and prices. Many analysts even participate in conference calls where they can get information to better make sense of the numbers.
InvestorsObserver averages the ratings provided by analysts and then ranks their score as a percent against the market. This allows you to compare stocks in a more comprehensive fashion than with the typical buy/sell/hold ranking.
What's Happening With Sellas Life Sciences Group Inc Stock Today?
Sellas Life Sciences Group Inc (SLS) stock is down -12.5% while the S&P 500 is higher by 0.37% as of 2:49 PM on Wednesday, Sep 2. SLS is down -$0.26 from the previous closing price of $2.08 on volume of 463,261 shares. Over the past year the S&P 500 has risen 21.80% while SLS is down -73.78%. SLS lost -$5.54 per share the over the last 12 months.
Click Here to get the full report on Sellas Life Sciences Group Inc (SLS) Stock.
